Chest Computed Tomography-Based Radiomics for the Diagnosis and Prognosis of Pulmonary Hypertension

基于胸部计算机断层扫描的放射组学在肺动脉高压的诊断和预后中的应用

阅读:1

Abstract

BACKGROUND: Imaging technique has emerged as an innovative tool for diagnosing and monitoring patients with pulmonary hypertension (PH). Current studies in radiomics primarily focus on hemodynamics and cardiac function, whereas the assessment of pulmonary vessels is often neglected. This study aims to investigate the diagnostic and prognostic value of computed tomography pulmonary vascular radiomics in PH. METHODS: This multicenter study enrolled 193 patients with PH and 193 controls (102 symptomatic non-PH cases and 91 healthy volunteers) for diagnostic analysis, with external validation in 38 patients with PH and 38 controls. For prognostic analysis, 166 patients with PH were prospectively followed (median follow-up: 16 months; 96 clinical deterioration events), with external validation in 32 patients with PH (median follow-up: 7 months; 11 events). Pulmonary vascular radiomics features extracted from chest computed tomography were used to develop predictive models for PH diagnosis and prognosis. RESULTS: The diagnostic model integrating 7 radiomic and 3 clinical features achieved an area under the curve of 0.984 (95% CI, 0.959-0.995) in the derivation cohort and 0.980 (0.901-1.000) in external validation. For exploratory pulmonary arterial hypertension subtyping, the model incorporating 8 radiomic and 2 clinical features yielded an area under the curve of 0.898 (0.825-0.972) internally and 0.877 (0.352-1.000) externally. The prognostic radiomic-clinical model outperformed the European Society of Cardiology 4-strata risk assessment, with a 2-year area under the curve of 0.866 (0.8-0.942) versus 0.709 (0.648-0.789). CONCLUSIONS: The radiomics-based models have strong diagnostic and prognostic capabilities for PH and can also successfully differentiate pulmonary arterial hypertension. This suggests the potential of radiomics to discern PH with different clinical risks, which may facilitate personalized drug therapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。